- Recce Pharmaceuticals (RCE) completes dosing its male and female subjects in its phase I/II UTI clinical trial with Scientia Research
- The trial evaluates R327 anti-infective at faster infusion rates of 30 minutes at a dosage of 3000mg, which is found to be safe and well-tolerated in all patients
- Following this the company is utilising an Independent Safety Committee to review the cohort dosing data, which will aid in its next cohort recruitment now underway
- RCE CEO James Graham says the results further support R327’s potential as a treatment option for patients suffering from UTIs
- RCE shares are up 5.38 per cent, trading at 49 cents at 11:54 am AEST
Recce Pharmaceuticals (RCE) has completed dosing male and female subjects in its phase I/II UTI-urosepsis clinical trial with Scientia Research to evaluate its R327 anti-infective at faster infusion rates.
The company proved the drug was safe and well-tolerated at a faster infusion rate of 30 minutes at a 3000-milligram dosage.
Following these results, the company has selected an Independent Safety Committee to review the complete cohort dosing data and will aid in RCE’s next cohort recruitment, which is now underway.
“We are pleased to see R327 administered at a faster infusion rate of 3000mg, reinforcing R327’s safety profile among male and female subjects,” RCE Chief Executive Officer James Graham said.
“These results further support R327’s potential as a treatment option, positioning it as a therapy for patients suffering from UTI/urosepsis, which is responsible for about 30 per cent of all sepsis infections.”
RCE shares were up 5.38 per cent, trading at 49 cents at 11:54 am AEST.